Compare BXSL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXSL | IBRX |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.1B |
| IPO Year | 2018 | 2015 |
| Metric | BXSL | IBRX |
|---|---|---|
| Price | $24.41 | $9.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $27.86 | $12.60 |
| AVG Volume (30 Days) | 2.7M | ★ 31.5M |
| Earning Date | 05-28-2026 | 05-18-2026 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 2.46 | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $2.05 | $93.25 |
| Revenue Next Year | N/A | $149.39 |
| P/E Ratio | $9.93 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $23.30 | $1.83 |
| 52 Week High | $33.73 | $12.43 |
| Indicator | BXSL | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 59.03 |
| Support Level | N/A | $2.23 |
| Resistance Level | $27.04 | $12.43 |
| Average True Range (ATR) | 0.66 | 1.32 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 46.37 | 50.38 |
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.